Daniel Tang to lead ICON Asia-Pacific
This article was originally published in Scrip
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has appointed Dr Daniel Tang general manager of Asia Pacific. Dr Tang will lead the development of ICON's early phase activities across the region. He has over 15 years' experience in drug research having previously served as vice-president of operations and bioassay/DMPK at Frontage Laboratories.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.